Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H17NO2 |
Molecular Weight | 267.3224 |
Optical Activity | ( - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCC3=C(C=C(O)C(O)=C3)[C@]1([H])C4=C(CN2)C=CC=C4
InChI
InChIKey=BGOQGUHWXBGXJW-YOEHRIQHSA-N
InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m0/s1
Molecular Formula | C17H17NO2 |
Molecular Weight | 267.3224 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. Dihydrexidine was shown to stimulate cyclic AMP synthesis just as well or better than dopamine. It was the first dopamine D1 receptor agonist that had potent antiparkinsonian activity in a primate model of Parkinson's disease. Dihydrexidine produces hypothermia. Dihydrexidine has been shown to alleviate cognitive deficits or enhance cognitive performance in a number of animal models of cognition. It is under investigation for the improving the cognitive and working memory deficits in schizophrenia and schizotypal disorder.
CNS Activity
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17596915
20 mg over 15 min
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:22:57 GMT 2023
by
admin
on
Sat Dec 16 14:22:57 GMT 2023
|
Record UNII |
U4MPC92UC2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
757161-85-6
Created by
admin on Sat Dec 16 14:22:57 GMT 2023 , Edited by admin on Sat Dec 16 14:22:57 GMT 2023
|
PRIMARY | |||
|
U4MPC92UC2
Created by
admin on Sat Dec 16 14:22:57 GMT 2023 , Edited by admin on Sat Dec 16 14:22:57 GMT 2023
|
PRIMARY | |||
|
5311070
Created by
admin on Sat Dec 16 14:22:57 GMT 2023 , Edited by admin on Sat Dec 16 14:22:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
INNOVATOR->PARENT | |||
|
ENANTIOMER -> ENANTIOMER |
|
||
|
RACEMATE -> ENANTIOMER |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |